Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:ELUT NASDAQ:IVA NASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$4.81-3.6%$3.82$1.14▼$7.20$298.88M0.91.16 million shs1.51 million shsELUTElutia$2.04+0.5%$1.96$1.61▼$5.12$83.46M0.8825,923 shs15,286 shsIVAInventiva$3.22-3.9%$3.28$1.53▼$4.05$319.99M0.7317,937 shs7,649 shsSGMTSagimet Biosciences$8.25-5.1%$7.64$1.73▼$11.41$266.56M3.36784,120 shs826,826 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-3.61%-6.96%+20.25%+71.17%+22.08%ELUTElutia+0.49%+6.25%-5.56%0.00%-44.11%IVAInventiva-2.72%+2.74%+8.05%-4.73%+40.61%SGMTSagimet Biosciences-5.06%-19.43%+1.73%+115.40%+145.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDXAldeyra Therapeutics1.4092 of 5 stars3.51.00.00.00.60.80.6ELUTElutia3.4514 of 5 stars3.55.00.00.01.93.30.6IVAInventiva2.5144 of 5 stars3.43.00.00.02.11.70.6SGMTSagimet Biosciences2.9703 of 5 stars3.54.00.00.02.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 3.00Buy$9.5097.51% UpsideELUTElutia 3.00Buy$8.00292.16% UpsideIVAInventiva 2.80Moderate Buy$10.40222.98% UpsideSGMTSagimet Biosciences 3.00Buy$26.83225.25% UpsideCurrent Analyst Ratings BreakdownLatest ELUT, SGMT, ALDX, and IVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025SGMTSagimet BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$28.006/6/2025SGMTSagimet BiosciencesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $27.005/19/2025ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/9/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$1.19 per shareN/AELUTElutia$24.38M3.44N/AN/A($1.31) per share-1.56IVAInventiva$9.95M30.96N/AN/A($1.21) per share-2.66SGMTSagimet Biosciences$2M126.51N/AN/A$5.08 per share1.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$55.85M-$0.97N/AN/AN/AN/A-72.58%-52.32%8/7/2025 (Estimated)ELUTElutia-$53.95M-$1.93N/AN/AN/A-168.23%N/A-96.70%8/6/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)SGMTSagimet Biosciences-$45.57M-$1.76N/AN/AN/AN/A-35.21%-34.09%8/13/2025 (Estimated)Latest ELUT, SGMT, ALDX, and IVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SGMTSagimet Biosciences-$0.57N/AN/AN/AN/AN/A8/7/2025Q2 2025ALDXAldeyra Therapeutics-$0.24N/AN/AN/AN/AN/A5/14/2025Q1 2025ALDXAldeyra Therapeutics-$0.25-$0.17+$0.08-$0.17($0.80) millionN/A5/8/2025Q1 2025ELUTElutia-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million5/8/2025Q1 2025SGMTSagimet Biosciences-$0.79-$0.56+$0.23-$0.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra Therapeutics0.246.496.49ELUTElutiaN/A0.810.70IVAInventivaN/A0.920.92SGMTSagimet BiosciencesN/A20.3420.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%ELUTElutia74.03%IVAInventiva19.06%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics9.60%ELUTElutia27.60%IVAInventiva32.00%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1059.90 million54.15 millionOptionableELUTElutia18041.12 million29.77 millionNot OptionableIVAInventiva10095.66 million65.05 millionNot OptionableSGMTSagimet Biosciences830.67 million26.17 millionOptionableELUT, SGMT, ALDX, and IVA HeadlinesRecent News About These CompaniesAnalysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $26.83July 29, 2025 | americanbankingnews.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by AnalystsJuly 26, 2025 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Coverage Initiated at Canaccord Genuity GroupJuly 25, 2025 | marketbeat.comDavid Happel Sells 65,478 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) StockJuly 25, 2025 | americanbankingnews.comSagimet gains as Canaccord Genuity starts with Buy on potential against MASHJuly 24, 2025 | msn.comSagimet Biosciences Inc. (NASDAQ:SGMT) Insider Eduardo Bruno Martins Sells 8,277 SharesJuly 24, 2025 | marketbeat.comInsider Selling: Sagimet Biosciences Inc. (NASDAQ:SGMT) General Counsel Sells 10,780 Shares of StockJuly 24, 2025 | marketbeat.comInsider Selling: Sagimet Biosciences Inc. (NASDAQ:SGMT) CEO Sells 65,478 Shares of StockJuly 24, 2025 | marketbeat.comInsider Selling: Sagimet Biosciences Inc. (NASDAQ:SGMT) Insider Sells 8,277 Shares of StockJuly 24, 2025 | insidertrades.comSagimet Biosciences (NASDAQ:SGMT) Trading Up 8.7% - Here's WhyJuly 23, 2025 | marketbeat.comWe Think Sagimet Biosciences (NASDAQ:SGMT) Can Afford To Drive Business GrowthJuly 16, 2025 | finance.yahoo.comSGMT Sagimet Biosciences Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comSagimet Biosciences Inc News (SGMT) - Investing.comJune 27, 2025 | investing.comSagimet Biosciences Inc. (SGMT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comSagimet Biosciences Inc.June 14, 2025 | wsj.comSagimet Biosciences updates executive compensationJune 12, 2025 | investing.comWhat Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?June 11, 2025 | zacks.comSagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to ...June 11, 2025 | morningstar.comMWall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should KnowJune 9, 2025 | zacks.comSagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025June 9, 2025 | globenewswire.comSagimet Biosciences Analyst RatingsJune 5, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELUT, SGMT, ALDX, and IVA Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$4.81 -0.18 (-3.61%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.87 +0.06 (+1.25%) As of 08/1/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Elutia NASDAQ:ELUT$2.04 +0.01 (+0.49%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.04 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Inventiva NASDAQ:IVA$3.28 -0.07 (-2.09%) As of 08/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Sagimet Biosciences NASDAQ:SGMT$8.25 -0.44 (-5.06%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.39 +0.14 (+1.68%) As of 08/1/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.